Common name |
B-Tg(hEGFR) MC38 | Catalog number | 322295 |
Aliases |
EGFR, ERBB, ERBB1, ERRP, HER1, NISBD2, PIG61, mENA, epidermal growth factor receptor |
Disease | Colon carcinoma |
Organism |
Mouse |
Strain | C57BL/6 |
Tissue types | Colon | Tissue | Colon |
B-Tg(hEGFR) MC38 cells were subcutaneously transplanted into homozygous B-hEGFR mice (n=6), and on 35 days post inoculation, tumor cells were harvested and assessed for human EGFR expression by flow cytometry. As shown, human EGFR was highly expressed on the surface of tumor cells. Therefore, B-Tg(hEGFR) MC38 cells can be used for in vivo efficacy studies of EGFR therapeutics.
Tumor growth curve & Body weight changes
Subcutaneous homograft tumor growth of B-Tg(hEGFR) MC38 cells.
B-Tg(hEGFR) MC38 cells (5x105, 1x106) and wild-type MC38 cells (5x105) were subcutaneously implanted into homozygous B-hEGFR mice (female, 5-8-week-old, n=6). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B) Body weight (Mean ± SEM). Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. As shown in panel A, B-Tg(hEGFR) MC38 cells were able to form tumors in vivo and can be used for efficacy studies.
B-Tg(hEGFR) MC38 tumor cells growth of individual mice.
B-Tg(hEGFR) MC38 cells (5x105, 1x106) and wild-type MC38 cells (5x105) were subcutaneously implanted into homozygous B-hEGFR mice (female, 5-8-week-old, n=6). As shown in panel, B-Tg(hEGFR) MC38 cells were able to establish tumors in vivo and can be used for efficacy studies.